肺炎支原体肺炎患儿T细胞亚群变化及匹多莫德的治疗作用

目的:探讨肺炎支原体患儿T细胞亚群变化及匹多莫德的治疗作用。方法:68例支原体肺炎患儿随机分为两组,两组均予静脉点滴阿齐霉素5天后,予以阿齐霉素口服,剂量和疗程相同。治疗组加匹多莫德口服,而对照组不用。采用流式细胞仪(FCM)检测68例支原体肺炎患儿外周血T细胞亚群,并以28例健康儿童作为正常对照。结果:支原体肺炎急性期外周血CD4+T细胞比例、CD4+/CD8+T细胞比值分别为(32.40±5.93)%和(1.12±0.43),与正常对照组相比明显下降(P<0.01);CD8+T细胞比例为(28.96±3.34)%,与正常对照组相比显著升高(P<0.01)。支原体肺炎患儿经匹多莫德治疗后外周血CD4+T细胞比例和CD4+/CD8+T细胞比值有明显上升(P<0.05);未经匹多莫德治疗的支原体肺炎患儿在治疗前后T细胞亚群各项指标均无显著性变化。支原体肺炎患儿匹多莫德治疗组平均病情反复次数较非匹多莫德治疗对照组明显下降(P<0.05)。结论:肺炎支原体肺炎患儿T细胞免疫功能低下,匹多莫德可提高机体免疫功能,对支原体肺炎的治疗有重要的临床意义。

Changes of T cell subgroups in children with Mycoplasma pneumoniae pneumonia and the effect of Pidotimod

Objective:To investigate the changes of T cell subgroups in children with Mycoplasma pneumoniae pneumonia and the effect of Pidotimod.Methods:68 children with Mycoplasma pneumoniae pneumonia(MPP) were enrolled and divided into therapeutic group and non-therapeutic group randomly(n=34).The children in both of the groups were treated with Azithromycin via intravenous drip for 5 days,followed by oral administration of Azithromycin.The dose and course of oral administration of Azithromycin in both of the groups were identical.Meanwhile,the therapeutic group was treated with Pidotimod and the non-therapeutic group remained untreated.The changes of T cell subgroups were measured by means of f1ow cytometry(FCM).In addition,28 healthy children were included as normal control group.Results:The percentage of CD4+T cells and the ratio of CD4+/CD8+T cells in the acute phase of MPP were(32.40±5.93)% and(1.12±0.43)% respectively,which was significantly lower than those in normal control controls(P<0.01).The percentage of CD8+T cells(28.96±3.34)% was significantly higher than that in normal control controls(P<0.01).After treatment with Pidotimod,the percentage of CD4+T cells and the ratio of CD4+/CD8+T cells in the children with MPP were significantly elevated(P<0.05),while there was no changes in T cell subgroups in the non-therapeutic children.In addition,The recurrent time of MPP in the therapeutic group was more frequent than that in the non-therapeutic group(P<0.05).Conclusion:The immune response in the children with MPP is depressed.The lower immune function can be recovered by Pidotimod,which may serve as a good immune regulator in the treatment of MPP.